,

Patent on oral formulations of a Pyridinone derivate

Abstract

This patent describes an oral formulation designed to selectively deliver the drug (a Pyridinone derivate) to the small intestine. The formulation consists of coated granules, pellets, beads, minicapsules, or minitablets containing a specific compound used for treating intestinal fibrosis, particularly fibrostenotic Crohn’s disease. The particles include a core material and an enteric coating polymer, ensuring targeted drug release. The patent also covers the method of preparation and its medical use. [1]

The delayed-release oral formulation is composed of coated microcrystalline cellulose pellets (CELLETS®, CELLETS® 500) as core material, ranging in size from 100 to 1,400 µm. The drug is a Pyridinone derivate, used for treating fibrostenotic Crohn’s disease, is protected by an enteric coating to ensure release in the intestine. The drug release is triggered by a pH range of 6.2 to 6.8, allowing for topical availability in the ileum. The patent also details the preparation method and medical applications.

Document information

Document Type and Number: (“ORAL FORMULATION OF A PYRIDINONE DERIVATE AND USE THEREOF IN PROPHYLAXIS AND/OR TREATMENT OF INTESTINAL FIBROSIS”)
Kind Code: A1

Inventors:

Wilhelm, Rudolf (Bischweier, DE)
Tewes, Bernhard (Vörstetten, DE)
Greinwald, Roland (Kenzingen, DE)

References

[1] ORAL FORMULATION OF A PYRIDINONE DERIVATE AND USE THEREOF IN PROPHYLAXIS AND/OR TREATMENT OF INTESTINAL FIBROSIS – Dr. Falk Pharma GmbH

/by